Spiral Therapeutics is a clinical-stage pharmaceutical company delivering novel therapies for hearing loss. Their lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of Ménière’s disease.

Spiral's precise delivery platform is uniquely suited to deliver a wide range of drugs to the ear. They have developed formulations that have the potential to achieve months of residence in the middle ear.

Spiral used this pitch deck created by Vip Sitaraman to raise $8.3M in funding for Phase II clinical trials, led by Esperante Ventures and Ferring Ventures.